A Comparative Pharmacokinetic and Safety Study of Chimeric Monoclonal Antibody ch14.18 With Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF), Interleukin-2 (IL-2) and Isotretinoin in High Risk Neuroblastoma Patients Following Myeloablative Therapy

Trial Profile

A Comparative Pharmacokinetic and Safety Study of Chimeric Monoclonal Antibody ch14.18 With Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF), Interleukin-2 (IL-2) and Isotretinoin in High Risk Neuroblastoma Patients Following Myeloablative Therapy

Completed
Phase of Trial: Phase I/II

Latest Information Update: 01 Feb 2016

At a glance

  • Drugs Dinutuximab (Primary) ; Aldesleukin; Granulocyte macrophage colony stimulating factor; Isotretinoin
  • Indications Neuroblastoma
  • Focus Pharmacokinetics
  • Sponsors United Therapeutics Corporation
  • Most Recent Events

    • 18 Mar 2014 Trial status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 02 Dec 2013 Planned end date changed from 1 Jul 2013 to 1 Feb 2014 as reported by ClinicalTrials.gov.
    • 02 Dec 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top